# Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

> **NCT06056310** · PHASE1 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Xevinapant
- **DRUG:** Cisplatin
- **RADIATION:** intensity-modulated radiation therapy (IMRT)

## Key facts

- **NCT ID:** NCT06056310
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-18
- **Primary completion:** 2024-08-20
- **Final completion:** 2024-08-20
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056310, "Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06056310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*